| abstract |
The invention provides a method of screening, in an in vitro system, of an agent useful in the treatment of oxytocin or vasopressin related disorders or conditions wherein said agent is able to modulate the inhibition by oxytocin of a vasopressin-activated neuron in the central amygdala after oxytocin sensitive neurons activation from the central amygdala, said method comprising the steps of: a) co-contacting an oxytocin agonist-or antagonist- and said agent with oxytocin sensitive neurons from the central amygdala, b) detecting whether said agent activates or inhibits vasopressin sensitive neurons of the central amygdala. |